Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP3 | O14638 | 1/20 | 0.45 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 8/20 | 0.35 |
| ▸ | GRM5 | P41594 | 4/20 | 0.35 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.35 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.35 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20209705 | 0.79 | ENPP3 (0.46) | ENPP3ENPP1DYRK1ASMPD3GRM1 | |
| SCHEMBL22815779 | 0.77 | ENPP3 (0.45) | ENPP3ENPP1DYRK1ASMPD3GRM1 | |
| SCHEMBL6951047 | 0.77 | MGAM (0.38) | DYRK1ACAMKK1CAMKK2NOTUM | |
| SCHEMBL30292976 | 0.75 | CCR1 (0.45) | DYRK1ACAMKK1CAMKK2NOTUM | |
| SCHEMBL256209 | 0.75 | CCR1 (0.45) | DYRK1ACAMKK1CAMKK2NOTUM | |
| SCHEMBL27439703 | 0.74 | DYRK1A (0.59) | DYRK1ASMPD3HTR6 | |
| SCHEMBL20674217 | 0.73 | NOTUM (0.40) | DYRK1ACAMKK1CAMKK2NOTUM | |
| SCHEMBL2727909 | 0.73 | ENPP3 (0.40) | ENPP3ENPP1DYRK1ACAMKK1CAMKK2 | |
| SCHEMBL21855983 | 0.73 | CAMKK1 (0.36) | DYRK1ACAMKK1CAMKK2NOTUM | |
| SCHEMBL10222527 | 0.73 | F2RL1 (0.38) | DYRK1ACAMKK1CAMKK2NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340485-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230340485-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230295622-A1 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295622-A1 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230256001-A1 | MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230190785-A1 | COMPOSITIONS AND METHODS FOR SILENCING DNAJC15 GENE EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230190785-A1 | COMPOSITIONS AND METHODS FOR SILENCING DNAJC15 GENE EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2021202443-A2 | COMPOSITIONS AND METHODS FOR SILENCING DNAJC15 GENE EXPRESSION | ALNYLAM PHARMACEUCTICALS, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190785-A1 | COMPOSITIONS AND METHODS FOR SILENCING DNAJC15 GENE EXPRESSION | DNAJC13, DNAJC5, DNAJC7 | ENPP3 3008/4885ENPP1 2991/4885DYRK1A 2578/4885 |
| US-20230256001-A1 | MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT | ADAR, SNRPE, ASGR1 | ENPP3 458/4885ENPP1 562/4885DYRK1A 1652/4885 |
| US-20230295622-A1 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | MYOF, MYO3A, MYO3B | ENPP3 3194/4885ENPP1 3196/4885DYRK1A 2960/4885 |
| US-20230340485-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALK, DGKG, EIF2AK2 | ENPP3 1641/4885ENPP1 1526/4885DYRK1A 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.